Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
EQRX EQRx
2.500+0.060+2.46%
Close
02/07 16:00 ET
2.5000.0000.00%
Post Mkt Price 02/07 16:01 ET
High
2.520
Open
2.450
Turnover
5.22M
Low
2.440
Pre Close
2.440
Volume
2.10M
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
We Think EQRx (NASDAQ:EQRX) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares
Softbank Group Says Determined To Sell Some Or All Holdings Of Shares Of EQRx In Open Market, Private Transactions
Softbank Group Says Determined To Sell Some Or All Holdings Of Shares Of EQRx In Open Market, Private Transactions
EQRx to Present at the 41st Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and expanding access to innovative medicines for some of t
CLNE, IOVA and ATRA Are Among After Hour Mover
EQRx Says UK Regulator Accepts Marketing Authorization Application for Sugemalimab to Treat Lung Cancer
10:17 AM EST, 12/19/2022 (MT Newswires) -- EQRx (EQRX) said Monday the UK's Medicines and Healthcare products Regulatory Agency has accepted for review its marketing authorization application for suge
GPRO, SGMO and CALA Are Among After Hour Mover
Stocks That Hit 52-Week Lows On Thursday
 On Thursday, 241 companies hit new 52-week lows. Significant Points From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was Tesla (NASDAQ:TSLA).Versus Systems (NA
Clearmind, IMV Top Healthcare Gainers; Third Harmonic, Miromatrix Lead Losers' Pack
EQRx (NASDAQ:EQRX) Is In A Good Position To Deliver On Growth Plans
EQRx Submits Marketing Authorization Application for Non-Small Cell Lung Cancer Drug in EU
10:57 AM EST, 12/02/2022 (MT Newswires) -- EQRx (EQRX) said Friday that the European Medicines Agency has accepted and will review the marketing authorization application for its aumolertinib product
Company Overview
More
CM Life Sciences III, Inc. operates as a blank check company formed as a Delaware corporation for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded on January 25, 2021 and is headquartered in New York, NY.
CEO： Ms. Melanie I. Nallicheri
Market： NASDAQ
Listing Date： 04/07/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet